
News|Videos|September 21, 2026
How The Food Safety Surveillance Infrastructure Works in the US
Author(s)John Parkinson, Lynette Johnston, PhD
Fact checked by: Nicole Canfora Lupo
In the first episode of our new series looking at the food safety network, Lynette Johnston, PhD, offers insights into how the federal government surveillance infrastructure operates and how epidemiologists serve as food detectives in determining bacterial pathogens and potential foodborne outbreaks.
Advertisement
Advertisement
Last week, seed supplier Everything Sprouts agreed to initiate a recall of the alfalfa seed lot linked to a foodborne outbreak that sickened people this summer. This recalled seed lot was sold directly to sprout growers and wholesale distributors and may also have been sold at the retail level. Sprout growers and wholesale distributors who received the recalled seed lot have been contacted directly by the common seed supplier.1
Related to this article

CDC lists 5 active multistate outbreaks tied to oysters, raw milk cheese, sprouts, and pet turtles, with recalls in effect for 4 of them.

Charles M. Walworth, MD, of Labcorp discusses a new hepatitis D reflex pathway, internal data showing 8.3% of HBsAg-positive patients screened for HDV, and lessons from hepatitis C reflex testing.

Jean van Wyk, MBChB, MFPM, discussed the 5-year OPERA data from IDWeek 2026 as well as the anticipated CROWN study results.

Voceryq earned FDA accelerated approval for adults with RRP after 7 of 26 patients (27%) needed no surgery for 12 months in RRP-001; a confirmatory trial is required.

Cefiderocol MICs fell against Pseudomonas aeruginosa and Klebsiella pneumoniae, and the drug showed marked synergy with LL-37 against resistant Acinetobacter baumannii. Jacinda Abdul-Mutakabbir, PharmD, MPH, AAHIVP, discusses her team's findings around this therapy and these pathogens.

Shionogi data presented at IDWeek 2026 demonstrated a 76.7% clinical response with cefiderocol in carbapenem-resistant respiratory infections and high in vitro activity against resistant P aeruginosa VAP isolates. Christine Slover, PharmD, vice president, Infectious Diseases US Medical Affairs, Shionogi, offers insights on the data as well as clinical considerations for providers when weighing the antibiotic for patients.

As France confirms the first documented human Shamonda virus infection, a fatal encephalitis in a stem cell transplant recipient, this FAQ explains what the virus is, where it has spread, how the case was diagnosed, how the patient was likely infected and what clinicians should watch for.
Advertisement
Advertisement

